Brief: Vaxart Q3 Net Income USD -14.08 Million
13/11/2024 21:01
Nov 13 (Reuters) - Vaxart Q3 basic EPS USD -0.06. * Q3 operating income USD -14.475 million * Q3 operating expenses USD 19.408 million * Q3 pretax profit USD -14.062 million
Recent news on Vaxart
See all newsBrief: Vaxart Expands Intellectual Property Portfolio With European Patent Protecting Proprietary Norovirus Vaccine Technology
Vaxart Q2 revenue falls on lower government contract income
Brief: Vaxart Q2 Net Income USD -13.494 Million
Brief: Vaxart Enters Cooperation Agreement With Stockholder Group And Announces Board And Corporate Governance Enhancements
Vaxart Q1 revenue more than doubles on government contracts